Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 12/20 | 0.60 |
| ▸ | S1PR1 | P21453 | 9/20 | 0.60 |
| ▸ | DRD4 | P21917 | 5/20 | 0.55 |
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.53 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.50 |
| ▸ | GRK5 | P34947 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1602272 | 0.83 | S1PR1 (0.69) | S1PR5S1PR1S1PR3 | |
| SCHEMBL3042076 | 0.81 | S1PR1 (0.77) | S1PR5S1PR1S1PR4S1PR3 | |
| SCHEMBL20421173 | 0.78 | DRD4 (0.53) | DRD4DRD2HTR2ACHRM4 | |
| SCHEMBL2416119 | 0.78 | S1PR1 (0.62) | S1PR5S1PR1S1PR3 | |
| SCHEMBL565212 | 0.77 | S1PR5 (0.87) | S1PR5S1PR1S1PR4S1PR3GRK5 | |
| SCHEMBL1981574 | 0.77 | SLC6A9 (0.50) | S1PR5S1PR1S1PR4S1PR3 | |
| SCHEMBL3041365 | 0.76 | S1PR5 (0.68) | S1PR5S1PR1HTR2AS1PR4S1PR3 | |
| SCHEMBL15071959 | 0.76 | S1PR1 (0.58) | S1PR5S1PR1S1PR4S1PR3 | |
| SCHEMBL3031513 | 0.76 | S1PR5 (0.78) | S1PR5S1PR1HTR2AS1PR4GRK5 | |
| SCHEMBL3043605 | 0.76 | S1PR5 (1.00) | S1PR5S1PR1S1PR4S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102387704-A | Agonists and antagonists of the S1P5 receptor, and methods of uses thereof | ABBOTT LAB | 2012-03-21 | — | — | CN | claimed |
| EP-2395835-A1 | AGONISTS AND ANTAGONISTS OF THE SIP5 RECEPTOR, AND METHODS OF USES THEREOF | Abbott Laboratories (US) | 2011-12-21 | — | — | EP | claimed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | claimed |
| WO-2010093704-A1 | AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF | ABBOTT LABORATORIES (US) | 2010-08-19 | — | — | WO | claimed |
| CN-102387704-A | Agonists and antagonists of the S1P5 receptor, and methods of uses thereof | ABBOTT LAB | 2012-03-21 | — | — | CN | disclosed |
| EP-2395835-A1 | AGONISTS AND ANTAGONISTS OF THE SIP5 RECEPTOR, AND METHODS OF USES THEREOF | Abbott Laboratories (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2010093704-A1 | AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF | ABBOTT LABORATORIES (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010093704-A1 | AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF | ABBOTT LABORATORIES (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | S1PR5, LPAR5, S1PR1 | S1PR5 1/4885S1PR1 3/4885DRD4 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.